News
IDEAYA/Servier PKC drug aces uveal melanoma trial
Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
News
Data backs GSK's ovarian cancer blockbuster hopes
GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
R&D
From in silico to in vivo: Why development strategy now dete...
As discovery becomes faster and more accessible, the differentiator shifts downstream.
R&D
Changing Faces: Pharma and biotech, March 2026
A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
News
Chinese trial backs base-editing drug for thalassaemia
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
